FIM 2016 FIM vs Anastasiy Nifontova - Settlement

13 Mar 2919

In November 2016 the International Motorcycling Federation (FIM) has reported an anti-doping rule violation against the Russian rider Anastasiy Nifontova after her sample tested positive for the prohibited substance Meldonium. After notification a provisional suspension was ordered.

The Athlete demonstrated with medical evidence that the violation was not intentional because she underwent treatment for her health problems and had used prescribed medication which she mentioned on the Doping Control Form.

FIM accepts that the violation was not intentional due to the prescribed medication for a legitimate medical condition but deems that there are no grounds for No Significant Fault or Negligence.

The parties in this case reached a settlement agreement and accordingly on 13 March 2019 a 2 year period of ineligibility was imposed on the Athlete starting on the date of the provisional suspension, i.e. on 14 November 2016.

Neuro-Doping - a Serious Threat to the Integrity of Sport?

29 Jul 2020

Neuro-Doping : a Serious Threat to the Integrity of Sport? / Verner Møller, Ask Vest Christiansen. - (Neuroethics (2020) 29 July)

  • DOI: 10.1007/s12152-020-09446-4


Abstract

The formation of the World Anti-Doping Agency (WADA) in 1999 was spurred by the 1998 revelation of widespread use in professional cycling of erythropoietin (EPO). The drug was supposedly a real danger. The long-term consequences were unknown, but rumor said it made athletes’ blood thick as jam with clots and other circulatory fatalities likely consequences. Today the fear of EPO has dampened. However, new scientific avenues such as ‘neuro-doping’ have replaced EPO as emergent and imagined threats to athletes and to the integrity of sport. In this paper, we analyze the alleged threat from ‘neuro-doping’ in the following steps: First, we outline an understanding of ‘neuro-doping’ in a narrow sense, which we then put into context by looking at the phenomenon in a broader sense. Second, we highlight examples of societal perceptions of sport and science in order to shed light on where the concern for ‘neuro-doping’ comes from. Third, we address the more general fear of technology as a root for this concern. Fourth, we examine the evidence for the performance enhancing capacities of ‘neuro-doping’, where after we look at the obstacles for a ban on this technology. We conclude the analysis by stating that at present ‘neuro-doping’ cannot be considered a threat to the integrity of sport. Finally, however, we put this conclusion into perspective by examining what the most reasonable response would be if in the future neuro-stimulation techniques becomes an effective performance-enhancing mean in sport.

The Ethics of Motivational Neuro-Doping in Sport: praiseworthiness and Prizeworthiness

23 Jul 2020

The Ethics of Motivational Neuro-Doping in Sport : praiseworthiness and Prizeworthiness / Hilary Bowman-Smart, Julian Savulescu. - (Neuroethics (2020) 23 July)



Abstract

Motivational enhancement in sport – a form of ‘neuro-doping’ – can help athletes attain greater achievements in sport. A key question is whether or not that athlete deserves that achievement. We distinguish three concepts – praiseworthiness (whether the athlete deserves praise), prizeworthiness (whether the athlete deserves the prize), and admiration (pure admiration at the performance) – which are closely related. However, in sport, they can come apart. The most praiseworthy athlete may not be the most prizeworthy, and so on. Using a model of praiseworthiness as costly commitment to a valuable end, and situating prizeworthiness within the boundaries of the sport, we argue that motivational enhancement in some cases can be compatible with desert.

WADA - Strategic Plan 2020-2024

2 Jul 2020

Strategic Plan 2020-2024 / World Anti-Doping Agency (WADA). - Montreal : WADA, 2020



The World Anti-Doping Agency (WADA) has published its Five-Year Strategic Plan, which lays the foundation for WADA’s strategic activity for 2020-2024 as the Agency is ‘Leading Anti-Doping in a New Era’.

The Strategic Plan was agreed by WADA’s Executive Committee (ExCo) when they met virtually on 15 May 2020; and, was subsequently approved unanimously by the Agency’s Foundation Board by circulatory vote.

Our journey of reflection and discovery

In May 2019, WADA initiated development of the Strategic Plan with a commitment to soliciting feedback from key stakeholders within the anti-doping ecosystem; such as: athletes; representatives of the Sports Movement and Governments of the world; industry influencers; as well as, National Anti-Doping Organizations and WADA-accredited laboratories. The feedback acknowledged how much WADA had achieved over its 20-year history; how the Agency’s growth had helped spur on the global movement for doping-free sport; and, it also identified a number of areas where WADA could improve or focus more.

The Strategic Priorities

WADA defined the following Strategic Priorities, which address the key issues and challenges identified via our internal and external consultation:

- Lead: Lead by example by taking bold steps to proactively tackle emerging issues with agility and innovative solutions across all facets of anti-doping.
- Grow Impact: Expand the reach and impact of anti-doping programs by enhancing capacity building and knowledge sharing between Anti-Doping Organizations and empowering local program delivery.
- Be Athlete-Centered: Engage and empower athletes to contribute to the development of anti-doping policies, build an easier anti-doping journey for athletes, and increase the contribution that our programs deliver for athletes and their entourage so that they can build healthy and sustainable careers in sport.
- Collaborate and Unite: Engage and collaborate with everyone involved in anti-doping, in particular with the sports movement and public authorities, to increase support, unity and coherence in everyone’s efforts.
- Be Visible: Raise awareness and shape a proactive narrative that will demonstrate the positive impact of doping-free sport and WADA’s role.
- Perform: Provide greater value to our stakeholders by reducing operational complexities and maximizing impact and cost-effectiveness.

WADA - ONDCP Report to the United States Congress

26 Jun 2020

WADA - ONDCP Report to the United States Congress / World Anti-Doping Agency (WADA). - Montreal : WADA, 2020


The World Anti-Doping Agency (WADA) was deeply disappointed to read the United States Office of National Drug Control Policy (ONDCP) Report regarding WADA funding that it submitted to the U.S. Congress on 17 June and that was made public.

As the U.S. has been a Foundation Board member of WADA since the creation of the Agency in 1999, WADA was particularly troubled by the fact that the ONDCP made allegations towards the Agency without due regard for the facts or context and without having raised any of these concerns during WADA Board meetings.

In Respons WADA sent an annotated version of the ONDCP Report to the Director of the ONDCP, asking him to kindly transmit this version to the U.S. Congress so that the Congress, and/or the appropriations committee, can deliberate and decide on WADA’s future funding based on accurate information. This annotated version outlines (in red) the misleading information and inaccuracies that the Report contains, and what the Report omits in terms of factual information.

iNADO Update #2020-06

19 Jun 2020

iNADO Update (2020) 6 (19 June)
Institute of National Anti-Doping Organisations (iNADO)


Contents:

iNADO
- We welcome 14 RADOs as new Members
- Upcoming Webinar
- How Athletes can change the Sport for Good - by Olympic Athlete Nikki Hamblin
Testing
- PWC - Useful Guidelines in place for DCOs during COVID-19
Research
- Journalists reveal a massive Abuse of Pain-Killers in German Football
- Richard Pound: "The Russian Doping Scandal: Some Reflections on Responsibility in Sport Governance"
- Testimonials from Whistleblowers urge for better Practices
Legal
- The Impact of COVID-19 on Procedures in Sport Disputes Resolution
WADA
- Updates by WADA related to COVID-19
- Limited Supplementary Stakeholder Consultation Phase for the 2021 ISPPPI
International Federations
- FIA sets up Whistleblower Hotline
New at the Anti-Doping Knowledge
Center
- Recent cases of meat contamination

WADA - Athletes' Anti-Doping Rights Act

18 Jun 2020

Athletes' Anti-Doping Rights Act / World Anti-Doping Agency (WADA). - Montreal : WADA, 2020


The World Anti-Doping Agency (WADA) has published the final designed version of the Athletes’ Anti-Doping Rights Act (Act), which WADA’s Athlete Committee developed over two and half years in consultation with thousands of athletes and stakeholders worldwide.

The purpose of the Act, which is based on the 2021 World Anti-Doping Code (Code) and its related International Standards that take effect on 1 January 2021, is to ensure that the rights of all athletes worldwide to participate in doping-free sport are clearly set out, accessible, and universally applicable. The document was approved by WADA’s Executive Committee on 7 November 2019 during the World Conference on Doping in Sport in Katowice, Poland.

Developed by athletes, for athletes, the Act provides an outline of rights provided by the 2021 Code and International Standards in terms of equality of opportunity, fair testing programs, medical treatment, justice, accountability, education, data protection and more. It also makes recommendations around athletes’ rights to be part of a system that is free from corruption, that they are appropriately represented in terms of governance and decision-making, and that they have a right to legal aid.

This Act is made up of two parts. Part one sets out rights that are found in the Code and International Standards. Part two sets out recommended athlete rights, which are not found in the Code or Standards but are rights that athletes recommend that anti-doping organizations adopt for best practice.

Contents:

Part One
- Equality of opportunity
- Equitable and fair testing programms
- Medical treatment and protection of health rights
- Right to justice
- Right to accountability
- Whistleblower rights
- Right of education
- Right to data protection
- Right to compensation
- Protected persons rights
- Rights during a sample collection session
- Right to B sample analysis
- Other rights and freedoms
- Application and standing

Part Two
- Right to an anti-doping system
- Free from corruption
- Right to participate in governance and decision-makeing
- Right to legal support

Selective Androgen Receptor Modulators (SARMs) as Pharmacological Treatment for Muscle Wasting in Ongoing Clinical Trials

18 Jun 2020

Selective Androgen Receptor Modulators (SARMs) as Pharmacological Treatment for Muscle Wasting in Ongoing Clinical Trials / Guilherme Wesley Peixoto Da Fonseca, Elke Dworatzek, Nicole Ebner, Stephan Von Haehling. - (Expert Opinion on Investigational Drugs (2020) 18 June; p. 1-11)

  • PMID: 32476495
  • DOI: 10.1080/13543784.2020.1777275


Abstract

Introduction: Skeletal muscle wasting is a frequent clinical problem encountered in patients with chronic diseases. Increased levels of inflammatory markers play a role in the imbalance between muscle protein synthesis and degradation. Although testosterone has long been proposed as a treatment for patients with muscle wasting, undesirable side effects have raised concerns about prostatic hypertrophy in men as well as virilization in women. Selective androgen receptor modulators (SARMs) have demonstrated similar results like testosterone at improving lean body mass (LBM) with less side effects on androgen-dependent tissue.

Areas covered: This review outlines the ongoing clinical development in the field of SARMs and their effectiveness in improving body composition and physical function. The included articles were collected at pubmed.gov and analyzed integrally.

Expert opinion: There is an unmet clinical need for safe and effective anabolic compounds such as SARMs. Despite the effect on LBM shown by SARMs in phase II clinical trials, results on improved physical function and muscle strength are still lacking and long-term outcomes have to be assessed in these patients. Moreover, there is a need to determine the effect of resistance exercise training and protein intake associated with SARMs in the treatment of patients with muscle wasting.

World Anti-Doping Code 2021 - Changes from November 2019 to June 2020

16 Jun 2020

2021 World Anti-Doping Code : Changes from November 2019 to June 2020 / World Anti-Doping Agency (WADA). - Montreal : WADA, 2020


Summary document outlines the limited changes from the 26 November 2019 versions to the final version of the World Anti-Doping Code 2021 published 15 June 2020

World Anti-Doping Code 2021 - June 2020

15 Jun 2020

World Anti-Doping Code 2021 / World Anti-Doping Agency (WADA). - Montreal : WADA, 2020


The purposes of the World Anti-Doping Code and the World Anti-Doping Program which supports it are:

1.) To protect the Athletes’ fundamental right to participate in doping-free sport and thus promote health, fairness and equality for Athletes worldwide, and

2.) To ensure harmonized, coordinated and effective anti-doping programs at the international and national level with regard to the prevention of doping, including:

- Education — to raise awareness, inform, communicate, to instill values, develop life skills and decision-making capability to prevent intentional and unintentional anti-doping rule violations.

- Deterrence — to divert potential dopers, through ensuring that robust rules and sanctions are in place and salient for all stakeholders.

- Detection — an effective Testing and investigations system not only enhances a deterrent effect, but also is effective in protecting clean Athletes and the spirit of sport by catching those committing anti-doping rule violations, while also helping to disrupt anyone engaged in doping behavior.

- Enforcement — to adjudicate and sanction those found to have committed an anti-doping rule violation.

- Rule of law — to ensure that all relevant stakeholders have agreed to submit to the Code and the International Standards, and that all measures taken in application of their anti-doping programs respect the Code, the International Standards, and the principles of proportionality and human rights.

Category
  • Legal Source
  • Education
  • Science
  • Statistics
  • History
Country & language
  • Country
  • Language
Other filters
  • ADRV
  • Legal Terms
  • Sport/IFs
  • Other organisations
  • Laboratories
  • Analytical aspects
  • Doping classes
  • Substances
  • Medical terms
  • Various
  • Version
  • Document category
  • Document type
Publication period
Origin